What happens when you take atorvastatin with niacin?
Atorvastatin is a statin used to lower cholesterol and reduce the risk of heart attack and stroke. Niacin (vitamin B3, nicotinic acid) at cholesterol-treatment doses raises HDL, lowers triglycerides, and modestly lowers LDL. For years it was added on top of a statin in the hope of squeezing out extra heart protection. Two large trials in the 2010s showed that the combination does not deliver that benefit and instead increases the risk of muscle injury. Here is what happens when the two are taken together:
- Both drugs can stress muscle and liver tissue. Atorvastatin occasionally causes muscle symptoms, and high-dose niacin can also affect muscle and the liver. Taken together, those risks add up rather than cancel out.
- The combination amplifies muscle injury. Niacin alone rarely causes myopathy, but when paired with a statin — especially at cholesterol doses and especially with extended-release forms — the rate of muscle symptoms rises well above what a statin produces on its own.
- Worst case is rhabdomyolysis. Rarely, severe muscle breakdown can release proteins that overwhelm the kidneys. This is uncommon, but it is the outcome the muscle-injury signal points toward.
- Niacin carries its own metabolic costs. In the trials, niacin was linked to worsening blood-sugar control and new diabetes diagnoses, plus excess gastrointestinal bleeding and infections — harms that stack on top of the muscle concern.
- No matching reward. Despite the cholesterol numbers moving in a favorable direction, neither large trial found fewer heart attacks or strokes from adding niacin to a statin. The risk went up while the benefit stayed flat.
This concern applies to cholesterol-treatment doses of niacin, not to the tiny nutritional amount found in a daily multivitamin.
Why is this important?
This is not a theoretical interaction. It is one of the most rigorously studied combinations in modern cardiology, and the evidence reshaped clinical guidelines.
Two large randomized trials defined the current understanding. The AIM-HIGH trial (2011) randomized patients with cardiovascular disease and well-controlled LDL on a statin to extended-release niacin or placebo, and was stopped early for futility — no added cardiovascular benefit from niacin. The much larger HPS2-THRIVE trial (reported 2013), randomized more than 25,000 patients on statin therapy to extended-release niacin (with laropiprant) or placebo. It also found no cardiovascular benefit, and it documented a roughly fourfold increase in the rate of myopathy in the niacin group, along with excess new-onset diabetes, gastrointestinal bleeding, and infections.
HPS2-THRIVE specifically tested simvastatin, but the muscle concern is generally extended to atorvastatin and other statins because the mechanism is shared across the class. On the strength of these findings, major lipid bodies — including the National Lipid Association — moved away from recommending routine cholesterol-dose niacin for patients already optimized on a statin, and several niacin-statin combination products were withdrawn from many markets.
When the benefit is absent and the harm signal is consistent across tens of thousands of patients, the decision is no longer about cholesterol numbers — it is about avoiding preventable injury.
What should you do?
The core principle: do not add cholesterol-dose niacin to atorvastatin on your own, and review any cholesterol add-on with your doctor or pharmacist first.
Before any change: If you are on atorvastatin and thinking about niacin for cholesterol, talk to your prescriber before starting. Bring a full list of everything you take, including over-the-counter "flush-free" or extended-release niacin, which many people do not think of as a drug. Ask whether a safer, better-proven add-on fits your situation — modern options such as ezetimibe, icosapent ethyl, PCSK9 inhibitors, or bempedoic acid often address the same problem with a cleaner safety profile.
Every day, if you are on the combination under medical supervision: Some people are placed on both for a specific reason, such as severe high triglycerides that did not respond to a statin alone. If that is you, stay on it only under your prescriber's guidance and agreed monitoring. Watch for new or worsening muscle pain, weakness, unusual tiredness, or dark urine, and for signs of liver trouble such as yellowing skin or eyes, nausea, loss of appetite, or pain in the upper-right abdomen. Report any of these promptly rather than waiting.
After any change: If niacin is started, stopped, or its dose is adjusted, your prescriber may check blood tests for muscle and liver enzymes and review your blood sugar. Do not stop atorvastatin on your own — statins are protective, and the problem here is the niacin add-on, not the statin itself.
Which specific products are affected?
The concern is with niacin taken at cholesterol-treatment strength for its lipid effect, not with the small nutritional amount in everyday vitamins. Affected products include:
- Prescription extended-release niacin (for example, Niaspan).
- Over-the-counter sustained-release or controlled-release niacin sold for cholesterol (for example, Slo-Niacin).
- Immediate-release niacin marketed for cholesterol benefit.
- Older fixed-dose niacin-statin combination pills such as niacin/simvastatin (Simcor) and niacin/lovastatin (Advicor), which have been withdrawn in many markets.
The interaction applies to all statins, not only atorvastatin; the strongest trial data come from simvastatin, and the muscle risk is treated as a class effect.
Two things that are not the concern: the small amount of niacin in a standard daily multivitamin, which is a nutritional dose rather than a cholesterol dose; and inositol hexanicotinate ("no-flush niacin"), which does not behave like true niacin — it does not produce the same interaction, but it also does not deliver the lipid effects people often expect.
The science behind it
Two large randomized controlled trials anchor this interaction, and both have been verified directly.
The HPS2-THRIVE Collaborative Group study (Eur Heart J 2013; PMID 23444397), a large randomized controlled trial, randomized 25,673 high-risk patients on statin-based therapy to extended-release niacin plus laropiprant or placebo. It found no reduction in major vascular events, and definite myopathy was roughly four times as common in the niacin group (relative risk about 4.4, 95% CI 2.6–7.5). The niacin group also had excess new-onset diabetes, worse glycemic control, gastrointestinal bleeding, and infections.
The AIM-HIGH trial (Boden WE et al., N Engl J Med 2011; PMID 22085343), a randomized controlled trial, randomized 3,414 patients with cardiovascular disease and well-controlled LDL on a statin to extended-release niacin or placebo. It was stopped early because adding niacin produced no incremental cardiovascular benefit.
Together these trials make the same point from two directions: in people already well treated with a statin, adding cholesterol-dose niacin does not improve heart outcomes, while the larger trial shows it clearly raises the risk of muscle injury and other harms.
Frequently Asked Questions
Is the niacin in my multivitamin a problem with atorvastatin?
No. The small nutritional amount of niacin in a standard multivitamin is not what these trials studied. The concern is cholesterol-treatment strength niacin taken specifically for its lipid effect.
I have heart disease — won't niacin add extra protection on top of my statin?
The trials say no. Both AIM-HIGH and HPS2-THRIVE found no reduction in heart attacks or strokes when niacin was added to a statin in people whose cholesterol was already well controlled.
Does "no-flush" niacin avoid the interaction?
Inositol hexanicotinate ("no-flush niacin") does not act like true niacin, so it does not produce the same interaction — but it also does not deliver the cholesterol benefits people usually expect from niacin.
What symptoms should make me call my doctor?
New or worsening muscle pain or weakness, unusual tiredness, dark urine, or signs of liver trouble (yellowing skin or eyes, nausea, loss of appetite, upper-right abdominal pain). Report these promptly.
Should I stop my atorvastatin?
No — not on your own. Statins are protective. If you are worried about a combination, the niacin add-on is the part to discuss with your prescriber, not the statin.
My doctor has me on both — is that wrong?
Not necessarily. Some people are placed on the combination for a specific reason, such as severe high triglycerides. The key is that this is a deliberate, monitored decision by a prescriber, not something to start on your own.
Key takeaways
- Adding cholesterol-dose niacin to atorvastatin raises the risk of muscle injury without improving heart outcomes in people already well treated with a statin.
- HPS2-THRIVE (25,673 patients) found roughly a fourfold increase in myopathy plus excess diabetes, bleeding, and infections; neither it nor AIM-HIGH showed cardiovascular benefit.
- The concern is class-wide for statins; the muscle risk applies to atorvastatin even though the strongest data come from simvastatin.
- The small amount of niacin in a multivitamin is not the concern — only cholesterol-treatment doses are.
- Do not start, stop, or change niacin on your own; review any cholesterol add-on with your doctor or pharmacist, and ask about better-proven alternatives.